Patient and caregiver preferences for once-weekly injection devices for the treatment of growth hormone deficiency
Jing Voon Chen, PhD1; Bradley S. Miller, MD, PhD2; Nicky Kelepouris, MD1; Ben Kantor, BASc3; Lisa Marin, BA3; Chris Platt, BS3; Kevin C.J. Yuen, MD, FRCP, FACE, FEAA4
MATERIALS AVAILABLE
Poster
Video
12:15 - 13:45
PDT
SAT-212
POSTER
Long-term safety and efficacy of somapacitan in short children born small for gestational age: 4-year results from a global phase 2 trial
Anders Juul1,2; Michael Højby3; Masanobu Kawai4; Agnès Linglart5; Jun Mori6, Nehama Zuckerman-Levin7; Philippe Backeljauw8; on behalf of the REAL 5 study group
MATERIALS AVAILABLE
Poster
12:15 - 13:45
PDT
SAT-185
POSTER
First real-world evidence of somapacitan therapy initiation in children with GHD from GloBE-Reg
Efficacy and safety of somapacitan in non-GHD adolescents with short stature: 26-week results from the REAL9 phase 3 study
Aristides Maniatis1; Michael Højby2; Muhammad Yazid Jalaludin3; Alexander A. L. Jorge4; Jun Mori5; Kamil Soltysik2; Renata Stawerska6,7; Agnéès Linglart8.
MATERIALS AVAILABLE
Poster
14:45 - 15:00
PDT
OR03-06
ORAL PRESENTATION
Acutely regulated genes in children born small for gestational age following daily and weekly growth hormone are predictive of first-year growth response
Terence Garner1; Philip Murray1,2; Michael Højby3; Ryan Anthony Ard3; Peter Clayton1,2; and Adam Stevens1
MATERIALS AVAILABLE
Slide
Monday, 14 July 2025
12:00 - 13:30
PDT
POSTER
Real-world Weight Loss Observed With Semaglutide And Tirzepatide In Patients With Overweight Or Obesity And Without Type 2 Diabetes
Carmen Ng1; Victoria Divino1; Julia Wang1; Joshua Toliver1; Marcio Buss1